-
Mashup Score: 0Delayed Diagnosis in Cerebral Venous Thrombosis: Associated Factors and Clinical Outcomes - 7 month(s) ago
Background Identifying factors associated with delayed diagnosis of cerebral venous thrombosis (CVT) can inform future strategies for early detection. Methods and Results We conducted a retrospecti…
Source: www.ahajournals.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 26
Background: Emerging data suggest that direct oral anticoagulants may be a suitable choice for anticoagulation for cerebral venous thrombosis (CVT). However, conducting high-quality trials in CVT is
Source: www.ahajournals.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 10:: Journal of Stroke - 11 month(s) ago
J Stroke. 2023; 25(2): 291-298. Published online: May 30, 2023 Timing and Predictors of Recanalization After Anticoagulation in Cerebral Venous Thrombosis Setareh Salehi Omran1 , Liqi Shu2, Allison Chang2, Neal S. Parikh3, Adeel S. Zubair4, Alexis N. Simpkins5, Mirjam R. Heldner6, Arsany Hakim7, Sami Al Kasab8, Thanh Nguyen9, Piers Klein9, Eric D. Goldstein2,…
Source: www.j-stroke.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 2Recanalization and Outcomes After Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis - 1 year(s) ago
Recanalization in cerebral venous thrombosis (CVT) can begin as early as one week after initiating therapeutic anticoagulation. The clinical significance of recanalization remains uncertain. We investigated the association between recanalization and functional outcomes, and explored predictors of recanalization.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0October 2022 Stroke Highlights - 1 year(s) ago
Home-Based Transcranial Direct Current Stimulation to Enhance Cognition in Stroke: Randomized Controlled TrialCognitive dysfunction is a significant contributor to disability and functional dependence poststroke, and therapies targeting cognitive recovery are lacking. Transcranial direct current stimulation (tDCS) has shown promising results in other neurodegenerative conditions, especially when…
Source: StrokeCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0New ESC Cardio-Oncology Guideline Aims to Reduce Cardiotoxicity - 2 year(s) ago
For the first time, the European Society of Cardiology has produced a guideline that, across 272 recommendations, sets out how cardiotoxicity risk can be managed along the cancer treatment pathway.
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3New ESC Cardio-Oncology Guideline Aims to Reduce Cardiotoxicity - 2 year(s) ago
For the first time, the European Society of Cardiology has produced a guideline that, across 272 recommendations, sets out how cardiotoxicity risk can be managed along the cancer treatment pathway.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3New ESC Cardio-Oncology Guideline Aims to Reduce Cardiotoxicity - 2 year(s) ago
For the first time, the European Society of Cardiology has produced a guideline that, across 272 recommendations, sets out how cardiotoxicity risk can be managed along the cancer treatment pathway.
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6COVID-19-Associated Cerebral Developmental Venous Anomaly Thrombosis With Hemorrhagic Transformation - 2 year(s) ago
Key PointDevelopmental venous anomaly thrombosis is a rare complication associated with hypercoagulable states, including COVID-19 infection.A 35-year-old man with a 1-week history of fever, cough, and myalgias presented with left hemiparesis and seizures requiring intubation. A COVID-19 polymerase chain reaction test was positive. No other thrombotic risk factors were identified. Neuroimaging…
Source: StrokeCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Study confirms increased CVT with AstraZeneca COVID vaccine - 2 year(s) ago
“Reassuringly, no consistent association was observed between the Pfizer and Moderna mRNA vaccines and these rare complications.”
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet
ACTION CVT sub study found that a quarter of #CVT patients were diagnosed more than 10 days after symptom onset. #AHAJournals @ava_liberman @EkaBakradze1 https://t.co/LO5nTELkna https://t.co/n4OJS6XUTf